Side Effect Probability Visualizer

Compare side effect rates for GLP-1 medications against placebo, sourced directly from FDA clinical trial data. Select one or more medications to compare.

Select medications to compare (select one or more):

Wegovy

Semaglutide 2.4mg · STEP 1-3 (pooled)

2.4mg weekly
Drug (2.4mg weekly)
Placebo
Nausea
44%vs16%
Diarrhea
30%vs16%
Vomiting
24%vs6%
Constipation
24%vs11%
Abdominal pain
20%vs10%
Headache
16%vs12%
Fatigue
11%vs8%
Dyspepsia
9%vs5%
Dizziness
8%vs6%
Abdominal distension
7%vs4%
Eructation
5%vs2%
Hypoglycemia
4%vs2%

Discontinuation — Drug

6.8%

Discontinuation — Placebo

3.2%

% of participants who discontinued due to adverse events in each arm.

Source: Wegovy FDA Prescribing Information, Table 3 — Pooled STEP 1, 3, 4 data (adverse events ≥2% and greater than placebo)

About This Data

All percentages are derived from the adverse event tables in each medication's FDA prescribing information, which in turn reflect pooled data from pivotal Phase 3 clinical trials. Side effects shown are those occurring in ≥3% of participants and at a higher rate than placebo.

Drug % is the percentage of participants in the active treatment arm who reported the side effect. Placebo % is the percentage in the placebo arm. The difference represents the attributable rate — how much the medication likely adds beyond baseline.

Discontinuation rate reflects the percentage of participants who stopped the medication due to adverse events in each arm of the trial. A higher discontinuation rate with drug vs placebo reflects medication tolerability.

Individual experience varies. These are population-level statistics from controlled trial conditions and may not reflect real-world use, especially with dose modifications.